Other
Research and development expense
Neurocrine Biosciences Research and development expense increased by 14.7% to $296.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.5%, from $263.20M to $296.20M. Over 4 years (FY 2021 to FY 2025), Research and development expense shows an upward trend with a 32.6% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ2 2019
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher spending typically signals a commitment to long-term innovation and future product pipelines, while significant cuts may signal a shift toward short-term profitability.
Detailed definition
This metric captures the investment in creating new products, improving existing technologies, and advancing internal ca...
Peer comparison
Standard metric for technology and hardware firms; highly comparable to R&D spending at peers.
Metric ID:
other_research_and_development_expense_excluding_acquire_88a3cdHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $74.80M | $92.70M | $87.40M | $102.20M | $135.90M | $107.70M | $118.00M | $139.50M | $145.80M | $142.20M | $137.50M | $159.40M | $191.10M | $195.00M | $185.60M | $263.20M | $244.30M | $250.00M | $258.20M | $296.20M |
| QoQ Change | — | +23.9% | -5.7% | +16.9% | +33.0% | -20.8% | +9.6% | +18.2% | +4.5% | -2.5% | -3.3% | +15.9% | +19.9% | +2.0% | -4.8% | +41.8% | -7.2% | +2.3% | +3.3% | +14.7% |
| YoY Change | — | — | — | — | +81.7% | +16.2% | +35.0% | +36.5% | +7.3% | +32.0% | +16.5% | +14.3% | +31.1% | +37.1% | +35.0% | +65.1% | +27.8% | +28.2% | +39.1% | +12.5% |
Range$74.80M – $296.20M
CAGR+33.6%
Avg YoY Growth+32.2%
Median YoY Growth+31.6%
Current Streak3 quarters growth
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $263.20M | $244.30M | $250.00M | $258.20M | $296.20M |
| Total | $263.20M | $244.30M | $250.00M | $258.20M | $296.20M |
Research and development expense at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's research and development expense?
- Neurocrine Biosciences (NBIX) reported research and development expense of $296.20M in Q1 2026.
- How has Neurocrine Biosciences's research and development expense changed year-over-year?
- Neurocrine Biosciences's research and development expense increased by 12.5% year-over-year, from $263.20M to $296.20M.
- What is the long-term trend for Neurocrine Biosciences's research and development expense?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's research and development expense has grown at a 32.6% compound annual growth rate (CAGR), from $328.10M to $1.02B.
- What does research and development expense mean?
- Spending on innovation and product development.